Visual and morphological outcomes of bevacizumab (Avastin) versus ranibizumab (Lucentis) treatment for retinal angiomatous proliferation

International Ophthalmology, 04/25/2012

Patients with retinal angiomatous proliferation might benefit from both intravitreal bevacizumab and ranibizumab treatments with stabilization of visual acuity over a longer period of time. Close follow–up should nevertheless be performed in this special subgroup because of the high recurrence rate.

Print Article Summary Cat 2 CME Report